ArticleBMC complementary medicine and therapies2024
Treatment of Shengqingtongqiao Decoction for mild cognitive impairment of white matter lesions study protocol for a randomized, double-blind, double-dummy, parallel controlled trial.
Article in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhite matter lesions(WML) is an important cause of mild cognitive impairment(MCI). Ginkgo biloba extracts (GBTs) are widely used to treat cognitive dysfunctions. But the treatment of MCI is still limited. Shenqingtongqiao Decoction(SQTQD), as a clinical empirical formula, has received good feedback in treating MCI of WML. However, there was a lack of solid clinical research on SQTQD in treating MCI. The purpose of this study is to evaluate the efficacy of SQTQD in the MCI patients of WML.
methodsThis is a randomized, double-blind, double-dummy, parallel-controlled trial. 80 participants will be assigned to receive SQTQD granules plus GBTs mimetics or SQTQD mimetic granules plus GBTs in a 1:1 ratio. The trial will last 24 weeks, including a 12-week intervention and 12-week follow-up. The primary outcome is MoCA and AVLT. The secondary outcome is a neuropsychological battery (including MMSE, SCWT, TMT, DST, SDMT, BNT, VFT, and CDT), quality of life(BI, ADL, and FAQ scores), emotion assessment(PHQ-9, GAD-7 score) , Fazekas and ARWMCs scale, and fMRI. Researchers will record any adverse events throughout the trial. DISCUSSION: This study will provide evidence to evaluate the efficacy and safety of SQTQD for MCI of WML compared with GBTs.
trial registrationThe trial is registered at Chinese Clinical Trial Registry: Chinese Clinical Trial Registry (Number: ChiCTR2300068552).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.